Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 160 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sofosbuvir Clear all
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease

NCT02301936
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lutherville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Community-based Treatment of Chronic Hepatitis C Monoinfection and Coinfection With HIV in the District of Columbia

NCT02339038
View directory record Official record
Conditions
HCV HIV
Interventions
Ledipasvir 90 mg and Sofosbuvir 400 mg
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 99 Years
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Randomised Study of Interferon-free Treatment for Recently Acquired Hepatitis C in PWID and People With HIV Coinfection.

NCT02625909
View directory record Official record
Conditions
Hepatitis C
Interventions
SOF/VEL for 6 weeks, SOF/VEL for 12 weeks
Drug
Lead sponsor
Kirby Institute
Government
Eligibility
18 Years and older
Enrollment
222 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 24, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Sofosbuvir With Pegylated Interferon and Ribavirin Hepatitis C Virus (HCV) Genotypes 1,4,5,6

NCT01329978
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Sofosbuvir, RBV, PEG
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
44
States / cities
Montgomery, Alabama • Jonesboro, Arkansas • Anaheim, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 26, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

NCT03809533
View directory record Official record
Conditions
Kidney Transplantation, Hepatitis C
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Amit D Tevar, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sofosbuvir/Velpatasvir Fixed Dose Combination With Ribavirin in Chronic HCV Infected Adults Who Participated in a Prior Gilead Sponsored HCV Treatment Study

NCT02300103
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
23
States / cities
San Diego, California • San Marcos, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Active, not recruiting Phase 4 Interventional

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

NCT03520660
View directory record Official record
Conditions
Diabetes Mellitus, Hepatitis C, Chronic, Cardiovascular Diseases
Interventions
Epclusa
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 120 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2032
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir + Ribavirin in Adolescents and Children With Genotype 2 or 3 Chronic HCV Infection

NCT02175758
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
3 Years to 17 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
16
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2019 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION)

NCT01604850
View directory record Official record
Conditions
Chronic Hepatitis C
Interventions
SOF, RBV, Placebo to match SOF, Placebo to match RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
51
States / cities
Coronado, California • Los Angeles, California • San Diego, California + 41 more
Source: ClinicalTrials.gov public record
Updated May 28, 2014 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir/Velpatasvir in Postpartum Women With Opioid Use Disorder and Chronic Hepatitis C Infection

NCT03057847
View directory record Official record
Conditions
Hepatitis C, Chronic, Opioid-use Disorder
Interventions
Sofosbuvir/Velpatasvir
Drug
Lead sponsor
Elizabeth Krans, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

NCT01559844
View directory record Official record
Conditions
Hepatitis C, Hepatocellular Carcinoma
Interventions
Sofosbuvir, Ribavirin
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
13
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2016 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional Results available

Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment

NCT03207399
View directory record Official record
Conditions
Hepatitis C, Chronic, Lung Transplant
Interventions
Epclusa
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 11, 2019 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 1 Interventional

Open-Label Hepatic Impairment Study

NCT01497327
View directory record Official record
Conditions
Hepatitis C
Interventions
PSI-352938, PSI-7977
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 4 Interventional Results available

Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant

NCT02533934
View directory record Official record
Conditions
HIV, Hepatitis C, Cirrhosis
Interventions
Harvoni
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
8
States / cities
San Francisco, California • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

A Study of of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus (HCV) Genotype 5 or 6 Infection

NCT02966795
View directory record Official record
Conditions
Hepatitis C Virus (HCV)
Interventions
Glecaprevir/Pibrentasvir
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • West Hollywood, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2021 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic HCV Infection

NCT02201940
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
741 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
34
States / cities
Little Rock, Arkansas • Long Beach, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional Results available

12 Weeks of Ledipasvir (LDV)/Sofosbuvir (SOF) With Weight-based Ribavirin vs. 24 Weeks of LDV/SOF

NCT02605304
View directory record Official record
Conditions
HIV-1 Infection, Hepatitis C
Interventions
Ledipasvir/sofosbuvir, Ribavirin
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated May 2, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Withdrawn Phase 4 Interventional

HCV Post-Exposure Prophylaxis for Health Care Workers

NCT03313414
View directory record Official record
Conditions
Hepatitis C
Interventions
Sofosbuvir/Velpatasvir Treatment for 14 days
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 21, 2020 · Synced Oct 19, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Digimeds to Optimize Adherence in Patients With Hepatitis C and Increased Risk for Nonadherence

NCT03164902
View directory record Official record
Conditions
Hepatitis C, Chronic, Nonadherence, Patient
Interventions
Digital Medicine
Device
Lead sponsor
Proteus Digital Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • San Francisco, California • Colorado Springs, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Sofosbuvir/Velpatasvir Fixed-Dose Combination in Adults With Chronic HCV Infection and Child-Pugh Class B Cirrhosis

NCT02201901
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
SOF/VEL, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
49
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection

NCT01924949
View directory record Official record
Conditions
Hepatitis C
Interventions
LDV/SOF
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2018 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional

Expanding the Pool in Orthotopic Heart Transplantation

NCT03222531
View directory record Official record
Conditions
Hepatitis C, Heart Transplant, Cardiac Transplant
Interventions
sofosbuvir/velpatasvir
Drug
Lead sponsor
Mary E. Keebler, MD
Other
Eligibility
18 Years to 71 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis

NCT02114177
View directory record Official record
Conditions
Hepatitis C Virus Infection
Interventions
Simeprevir, Sofosbuvir
Drug
Lead sponsor
Janssen Infectious Diseases BVBA
Industry
Eligibility
18 Years to 70 Years
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
38
States / cities
Dothan, Alabama • Bakersfield, California • Chula Vista, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2016 · Synced Oct 19, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Sofosbuvir and Ribavirin in Adults With Recurrent Chronic Hepatitis C Virus (HCV) Post Liver Transplant

NCT01687270
View directory record Official record
Conditions
Recurrent Chronic Hepatitis C Virus, Post Liver Transplant
Interventions
Sofosbuvir, RBV
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
8
States / cities
San Francisco, California • Indianapolis, Indiana • Kansas City, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2014 · Synced Oct 19, 2026, 10:15 AM EDT